Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
Public ClinicalTrials.gov record NCT02896101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (Pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).
Study identification
- NCT ID
- NCT02896101
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 755 participants
Conditions and interventions
Conditions
Interventions
- Pimecrolimus Cream, 1% Drug
- Elidel® (pimecrolimus) Cream Drug
- Placebo of Pimecrolimus Cream, 1% Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2016 (Type not available)
- Primary completion
- Jun 2017 (Actual)
- Completion
- Jun 2017 (Actual)
- Last update posted
- Jul 31, 2019
2016 – 2017
United States locations
- U.S. sites
- 27
- U.S. states
- 11
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site 4 | Hot Springs | Arkansas | — | — |
| Investigational Site 22 | Little Rock | Arkansas | — | — |
| Investigational Site 20 | Anaheim | California | — | — |
| Investigational Site 13 | Fremont | California | — | — |
| Investigational Site 26 | Norco | California | — | — |
| Investigational Site 17 | Doral | Florida | — | — |
| Investigational Site 9 | Hialeah | Florida | — | — |
| Investigational Site 16 | Miami | Florida | — | — |
| Investigational Site 18 | Miami | Florida | — | — |
| Investigational Site 19 | Miami | Florida | — | — |
| Investigational Site 25 | Miami | Florida | — | — |
| Investigational Site 8 | Miami | Florida | — | — |
| Investigational Site 12 | North Miami Beach | Florida | — | — |
| Investigational Site 3 | Ormond Beach | Florida | — | — |
| Investigational Site 7 | South Miami | Florida | — | — |
| Investigational Site 10 | Tampa | Florida | — | — |
| Investigational Site 24 | Tampa | Florida | — | — |
| Investigational Site 14 | West Palm Beach | Florida | — | — |
| Investigational Site 1 | Arlington Heights | Illinois | — | — |
| Investigational Site 21 | Lake Charles | Louisiana | — | — |
| Investigational Site 2 | Silver Spring | Maryland | — | — |
| Investigational Site 11 | Saint Joseph | Missouri | — | — |
| Investigational Site 27 | East Windsor | New Jersey | — | — |
| Investigational Site 5 | High Point | North Carolina | — | — |
| Investigational Site 23 | Raleigh | North Carolina | — | — |
| Investigational Site 15 | Cincinnati | Ohio | — | — |
| Investigational Site 6 | Nashville | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02896101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02896101 live on ClinicalTrials.gov.